

**VASTox plc**  
("VASTox" or "the Company")

## **Result of AGM**

**Oxford, UK, 3 June 2005** – VASTox plc (AIM: VOX), the Oxford-based drug discovery and services business focused on chemical genomics, is pleased to announce that all of the resolutions at the AGM of the Company, held today, were duly passed.

**Professor Stephen Davies, Non-Executive Chairman of Vastox, commented:**

"Since our successful flotation on AIM in October last year the Company has made significant progress with its proprietary programmes in Duchenne Muscular Dystrophy and Tuberculosis. Vastox has also signed several new service deals, relocated to new facilities in Oxfordshire and strengthened its Scientific Advisory Board in key areas of technology and drug development. The business is in a strong position for future growth."

**- END -**